EDITORIAL

1470 MicroRNAs in hepatocellular carcinoma treatment: Charting the path forward
Lin HT, Castaneda AFA, Krishna SG, Mumtaz K

1475 Innovative pathways allow safe discharge of mild acute pancreatitis from the emergency room
Kothari DJ, Sheth SG

1480 Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
Brilakis L, Theofilogiannakou E, Lykoudis PM

1488 Routine utilization of machine perfusion in liver transplantation: Ready for prime time?
Parente A, Sun K, Dutkowski P, Shapiro AJ, Schlegel A

1494 Advancements in Barrett’s esophagus detection: The role of artificial intelligence and its implications
Massironi S

REVIEW

1497 MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma
Wei QY, Jin F, Wang ZY, Li BJ, Cao WB, Sun ZY, Mo SJ

MINIREVIEWS

1524 Morphological and biochemical characteristics associated with autophagy in gastrointestinal diseases
Chang YF, Li JJ, Liu T, Wei CQ, Ma LW, Nikolenko VN, Chang WL

ORIGINAL ARTICLE

Retrospective Study

1533 Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors

Clinical Trials Study

1545 Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet

1556 Effects of Lactobacillus paracasei N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis
Hu YC, Ding XC, Liu HJ, Ma WL, Feng XY, Ma LN
**Propective Study**

1572 Washed microbiota transplantation for Crohn’s disease: A metagenomic, metatranscriptomic, and metabolomic-based study  

**Basic Study**

1588 Silent information regulator sirtuin 1 ameliorates acute liver failure via the p53/glutathione peroxidase 4/gasdermin D axis  

1609 Identification of an immune-related gene signature for predicting prognosis and immunotherapy efficacy in liver cancer via cell-cell communication  
Li JT, Zhang HM, Wang W, Wei DQ

**META-ANALYSIS**

1621 Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis  
Csontos A, Fazekas A, Szakó L, Farkas N, Papp C, Ferenczi S, Bellyei S, Hegyi P, Papp A

**CASE REPORT**

1636 Myocardial metastasis from ZEB1- and TWIST-positive spindle cell carcinoma of the esophagus: A case report  
Shibata Y, Ohmura H, Komatsu K, Sagara K, Matsuyama A, Nakano R, Baba E
ABOUT COVER
Editorial Board of World Journal of Gastroenterology, David L Morris, MD, FRCS (Ed), Professor, Department of Surgery, University of New South Wales, Sydney 2217, New South Wales, Australia. david.morris@unsw.edu.au

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xu Gao; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF
Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
March 21, 2024

COPYRIGHT
© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER
Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University; Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

POLICY OF CO-AUTHORS
https://www.wjgnet.com/bpg/gerinfo/310

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

PUBLISHING PARTNER'S OFFICIAL WEBSITE
https://www.shca.org.cn
https://www.zs-hospital.sh.cn

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: office@baishideng.com https://www.wjgnet.com
META-ANALYSIS

Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis

Armand Csontos, Alíz Fazekas, Lajos Szakó, Nelli Farkas, Csenge Papp, Szilárd Ferenczi, Szabolcs Bellyei, Péter Hegyi, András Papp

Abstract

BACKGROUND
Neoadjuvant therapy is an essential modality for reducing the clinical stage of esophageal cancer; however, the superiority of neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) is unclear. Therefore, a discussion of these two modalities is necessary.

AIM
To investigate the benefits and complications of neoadjuvant modalities.

METHODS
To address this concern, predefined criteria were established using the PICO
protocol. Two independent authors performed comprehensive searches using predetermined keywords. Statistical analyses were performed to identify significant differences between groups. Potential publication bias was visualized using funnel plots. The quality of the data was evaluated using the Risk of Bias Tool 2 (RoB2) and the GRADE approach.

RESULTS
Ten articles, including 1928 patients, were included for the analysis. Significant difference was detected in pathological complete response (pCR) \(P < 0.001; \text{OR: 0.27; 95}\% \text{CI: 0.16-0.46}\), 30-d mortality \(P = 0.015; \text{OR: 0.4; 95}\% \text{CI: 0.22-0.71}\) favoring the nCRT, and renal failure \(P = 0.039; \text{OR: 1.04; 95}\% \text{CI: 0.66-1.64}\) favoring the nCT. No significant differences were observed in terms of survival, local or distal recurrence, or other clinical or surgical complications. The result of RoB2 was moderate, and that of the GRADE approach was low or very low in almost all cases.

CONCLUSION
Although nCRT may have a higher pCR rate, it does not translate to greater long-term survival. Moreover, nCRT is associated with higher 30-d mortality, although the specific cause for postoperative complications could not be identified. In the case of nCT, toxic side effects are suspected, which can reduce the quality of life. Given the quality of available studies, further randomized trials are required.

Key Words: Neoadjuvant; Chemotherapy; Chemoradiotherapy; Esophageal cancer; Adenocarcinoma

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

INTRODUCTION

Epidemiology
Esophageal cancer (EC) is the eighth most prevalent cancer, with more than 500000 cases worldwide, and it is the sixth leading cause of tumor mortality. Squamous cell carcinoma (SCC) is still the leading subtype in the Asian EC Belt; however, in Western countries, such as North America, Oceania, and Western and Northern Europe, including Hungary, the incidence rate of adenocarcinoma (AC) has been increasing, surpassing that of SCC[1,2].

In the early stages, surgery can lead to full recovery; however, an advanced tumor stage at initial diagnosis can result in high morbidity and mortality rates[3]. Esophagectomy with radical lymphadenectomy is one of the most invasive gastrointestinal procedures. To improve treatment results, a multidisciplinary approach is important, including the application of the enhanced recovery after surgery protocol[4,5], the minimally invasive approach of esophagectomy[6], and neoadjuvant oncological therapy, which can decrease mortality by 25%-35% compared with that of surgery alone[7-9].

Impact of the topic
The superiority of neoadjuvant therapy has been proven in several meta-analyses[7-9]. Neoadjuvant chemotherapy (nCT) or preoperative neoadjuvant chemoradiotherapy (nCRT) can also improve oncologic endpoints[8-15], increase overall and progression-free surveillance, and pathological complete response (pCR); however, it may also be associated with numerous clinical or surgical side effects and impaired quality of life. Therefore, the cost-benefit balance of these modalities is still unclear, especially in cases of AC of the esophagus and esophagogastric junction (GEJ).

Literature background
Previous meta-analyses have numerous limitations, including patients with SCC and AC as a homogenous population. Therefore, the results cannot be clearly applied to either subtype.
Impact of our analysis
We performed a comprehensive, up-to-date investigation to determine whether nCT or nCRT yields more favorable results in the surgical treatment of AC of the esophagus and esophageal junction.

MATERIALS AND METHODS

Protocol registration
The objectives and methodologies of this meta-analysis were predefined in a protocol registered with PROSPERO[16]. The registration was accepted on November 01, 2023, under the number CRD42023478615.

Question of the review
To define the scope of this meta-analysis, we used the PICO protocol, focusing on patients with esophageal or cardiac AC, who received neoadjuvant therapy before surgery. Intervention assessed was preoperative nCT, which was compared to nCRT. We investigated the following outcomes: Survival, remission rate, mortality, short- and long-term clinical and surgical complications, and quality of life. First, we planned to investigate only randomized controlled trials (RCTs) to minimize the risk of bias; however, to achieve an adequate sample size and robust conclusions, propensity score matched and high-quality cohort studies were also included. Studies that did not strictly involve patients with AC were excluded.

Search strategy and search terms
We conducted a comprehensive search on September 15, 2023, using PubMed, Embase, Cochrane, Web of Science, and Scopus databases. We used previously defined search terms, including “neoadjuvant,” “chemotherapy,” “chemoradiotherapy,” “esophageal cancer,” “esophagectomy,” and other random keywords, and their variants. The retrieved datasets were imported into the EndNote (ver. x9.3.3; Alfasoft AB, Göteborg, Sweden) library.

Selection process
Two independent authors conducted the selection process using EndNote software. The Cohen’s kappa coefficients were calculated from these results. Discrepancies were resolved through consensus.

Data extraction
Data were extracted from text, figures, and tables of the included articles by two independent authors, with any discrepancies resolved through mutual agreement. Plot digitizer applications were used to collect data not provided in a numerical format[17]. Excel (Office 365, Microsoft, Redmond, WA, United States) datasheets were used to collect and organize the datasets. Descriptive data collected included study characteristics (author, year, type, and number of elements), patients demographics (age, sex, and performance), tumors (stage, location), and therapy (neoadjuvant regimen, surgical procedure). A meta-analysis was performed on outcomes with at least four homogeneous datasets. Outcomes, ineligible for statistical analysis, were qualitatively described. The outcomes assessed included pCR, surveillance (overall, progression-free, disease-free), mortality (30 or 90 d), tumor remission (local or distant), clinical complications (thromboembolism, respiratory and cardiac complications, renal failure, neutropenia) and surgical complication (anastomotic and chyle leakage, wound infection, bleeding, vocal cord paresis).

Statistical analysis
A random-effects meta-analysis was performed. Odds ratios (OR) with 95%CI were calculated to measure the effect size. To calculate the OR and pooled odds ratio, data for the total number of patients and those experiencing the event of interest in each group separately (referred as “raw data”) was extracted or calculated from the studies, where it was available. The results are presented as the odds of an event of interest in the experimental group vs the control group. The results were considered statistically significant if the pooled CI did not contain a null value. We also performed a supplementary analysis. Using the WebPlotDigitizer online tool, we digitalized the Kaplan-Meier (KM) curves published in the involved studies. Then, by applying the methodology of Guyot et al[18,19], we estimated the individual patient time-to-event data. Finally, we plotted all the available KM curves in the same figure. Using the estimated raw data, we calculated the hazard ratio (HR) within the studies and the pooled HR. A less than one HR suggests a smaller risk in the experimental group. The HR result was considered significant if it was not included in the confidence interval.

We visualized the findings in forest plots. Where applicable-the study number was large enough and not too heterogeneous—we also reported the prediction intervals (i.e., the expected range of effects of future studies) of the results. Additionally, between-study heterogeneity was described using Higgins and Thompson’s (I²) statistics (Higgins and Thompson[20], in 2002).

Publication bias was assessed by visual inspection of the funnel plots and calculation of the Harbord (modified Egger’s) test P value[21] for the OR effect size. We assumed the presence of a possible small study bias if the P value was < 10%. However, we kept in mind that the test has limited diagnostic assessment (below 10 studies). Potential outlier publications were explored using different influence measures and plots following the recommendations of Harrer et al [22]. All statistical analyses were performed with R (R Core Team 2023, v4.3.0)[23] using the meta (Schwarzar 2023, v6.2.1) [24] package for basic meta-analysis calculations and plots, IPDfromKM for raw data simulations, and the dmetar (v0.9.9000)[25] package for additional influential analysis calculations and plots. To pool the effect size, the pooled OR based on raw data was calculated using the Mantel-Haenszel method [26,27]. The Exact Mantel-Haenszel method
(without continuity correction) was used to handle zero-cell counts[28,29]. We used the Hartung-Knapp adjustment[30,31] for the CIs. To estimate the heterogeneity variance measure for the raw data OR calculation, the Paule-Mandel method[32] (recommended by Veroniki et al[33]) was used with the Q profile method for the confidence interval. Prediction interval calculations were based on the t-distribution. In the case of 0 cell counts, individual study OR with 95%CI was calculated by adding 0.5, as continuity correction (it was used only for visualization on forest plot). The pooled HR was calculated using classical inverse-variance meta-analysis of log-transformed HR ratios using the REML heterogeneity variance estimator.

Descriptive analyses were performed by calculating the means, standard deviations, and percentages. The mean estimates from the median and range were calculated as follows[34]:

**Risk of bias and certain of evidence**
The Risk of Bias Tool 2 (RoB2) and GRADE approaches were used to assess the quality of the articles and our research.

---

**RESULTS**

**Search process**
A total of 1285 articles were identified from the five databases. After removing duplicates, 1141 articles were screened, after which 485 and 153 articles were selected based on title and abstract screening, respectively. Subsequently, 125 full-text reports were examined, and eight studies were included in the quantitative synthesis. Cohen’s kappa indicated 99.74% substantial agreement (Cohen’s k: 0.77). Some reports could not be retrieved as they were conference abstracts [38]. Articles were excluded based on predefined criteria (83 articles), including those covering only SCCs (9 articles) or mixed group of ACs and SCCs (23 articles), mentioning no pathological subtype (1 article), and being a preliminary trial (1 article). Two additional articles were included during the screening of previous reviews. Overall, the analysis included ten articles. More information is provided in Figure 1.

**Characteristics of the studies**
Ten articles, published between 2011 and 2018, were included in this meta-analysis. Seven studies were conducted in Europe, two in Australia, and one in the United States[35-44]. Of the 10 studies, two were RCTs[43,44], four were propensity score-matched cohort study[39-42], and four were cohort study based on prospective institutional databases (clinical cancer registry)[35-38]. Six studies were single-center trials[36,39,40,42-44]. The articles collectively included data from 1928 patients, with 956 and 972 patients the nCT and nCRT groups, respectively. All included patients had esophageal ACs. Additional details are provided in Table 1.

**Characteristics of the patients**
The estimated mean age of the patients in both the groups was 60 years. The age range was 12-84 and 19-83 years. The nCT and nCRT groups included 829 (91%) and 857 (94%) male patients, respectively. Based on the available data, 84%, 16% and < 0.1% of the patients had American Society of Anesthesiologists scores of I-II, III, and IV, respectively. The patients had coronary morbidity (18%), diabetes mellitus (16%), pulmonary morbidity, chronic obstructive pulmonary disease (9%), history of malignancy (6%), and history of smoking (42%). More detailed information is summarized in Supplementary Table 1.

**Characteristics of the tumor and pathological approach**
Based on the available data, 99% of the tumors were diagnosed in the lower third of the esophagus or the GEJ. Clinical T-stages 1-4 accounted for 1%, 16%, 80%, and 3% of the cases, respectively. Nodal involvement was observed in 367 (61%) and 350 patients (59%) in the nCT and nCRT groups, respectively. Tumor differentiation was good in 2% and 1%, moderate in 36% and 31%, and poor in 57% and 64% of patients in the nCT and nCRT groups, respectively. Margin negative resection (R0) was performed in 696 (81%) and 800 (92%) patients in the nCT and nCRT groups. Pathological T-stage 1-4 accounted for 13%, 15%, 22%, and 47% of the cases, respectively, whereas N-stages 0-3 accounted for 4%, 16%, 80%, and 3% of the cases, respectively. Tumor regression grade (TRG, Mandard) stages 1-4 accounted for 13%, 15%, 22%, and 47% of the cases, respectively, whereas N-stages 0-3 accounted for 45%, 31%, 24%, and 42% (62%-22%) of the cases, respectively additional details are provided in Supplementary Table 2.

**Characteristics of the neoadjuvant therapy**
Neoadjuvant regimens were administered to patients in both groups. The most frequently used neoadjuvant drugs were cisplatin, 5-fluorouracil, and docetaxel. The CROSS protocol was the most commonly used protocol in the chemoradiation group. Additional details are provided in Table 2[7,8,10,45-48].

**Characteristics of the surgical procedure**
Based on the available data, Ivor-Lewis (trasthoracic), Orringer (transhiatal), McKeown (thoraco-abdomino-cervical) esophagectomies, and total gastrectomy were performed in 67%, 23%, 5%, and 4% of the patients, respectively. Minimally invasive or hybrid surgery techniques were performed in 27% and 51% of the patients, respectively, and open surgery was performed in only 23% of the patients. Two-field lymphadenectomy was the standard procedure in 74% of the patients, whereas three-field lymphadenectomy was performed in only 5% of the patients. Additional details are
### Table 1 Characteristic of the studies

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Design</th>
<th>Center</th>
<th>Country</th>
<th>Year</th>
<th>Number of patients</th>
<th>nCT</th>
<th>nCRT</th>
<th>AC, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stahl et al[44], 2017</td>
<td>RCT, Phase III</td>
<td>1</td>
<td>Germany</td>
<td>N/A</td>
<td>119</td>
<td>59</td>
<td>60</td>
<td>100</td>
</tr>
<tr>
<td>Burmeister et al[43], 2011</td>
<td>RCT, Phase II</td>
<td>1</td>
<td>Australia</td>
<td>N/A</td>
<td>75</td>
<td>36</td>
<td>39</td>
<td>100</td>
</tr>
<tr>
<td>Visser et al[42], 2018</td>
<td>PSM</td>
<td>1</td>
<td>Australia</td>
<td>2000-2017</td>
<td>262</td>
<td>131</td>
<td>131</td>
<td>100</td>
</tr>
<tr>
<td>Markar et al[41], 2017</td>
<td>PSM</td>
<td>10</td>
<td>United Kingdom</td>
<td>2001-2012</td>
<td>442</td>
<td>221</td>
<td>221</td>
<td>100</td>
</tr>
<tr>
<td>Goense et al[40], 2017</td>
<td>PSM</td>
<td>1</td>
<td>Netherlands</td>
<td>2006-2015</td>
<td>172</td>
<td>86</td>
<td>86</td>
<td>100</td>
</tr>
<tr>
<td>Favi et al[39], 2017</td>
<td>PSM</td>
<td>1</td>
<td>Germany</td>
<td>2011-2015</td>
<td>80</td>
<td>40</td>
<td>40</td>
<td>100</td>
</tr>
<tr>
<td>Anderegg et al[35], 2017</td>
<td>Cohort, PID</td>
<td>3</td>
<td>Netherlands</td>
<td>2005-2011</td>
<td>313</td>
<td>137</td>
<td>176</td>
<td>100</td>
</tr>
<tr>
<td>Spicer et al[38], 2016</td>
<td>Cohort, PID</td>
<td>3</td>
<td>United States</td>
<td>2002-2012</td>
<td>214</td>
<td>114</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Luc et al[36], 2015</td>
<td>Cohort, PID</td>
<td>1</td>
<td>France</td>
<td>2000-2012</td>
<td>116</td>
<td>61</td>
<td>55</td>
<td>100</td>
</tr>
<tr>
<td>Münch et al[37], 2018</td>
<td>Cohort, PCCR</td>
<td>70</td>
<td>Germany</td>
<td>1998-2014</td>
<td>135</td>
<td>71</td>
<td>64</td>
<td>100</td>
</tr>
</tbody>
</table>

RCT: Randomized controlled trial; PSM: Propensity score matched cohort; PID: Prospective institutional databases; PCCR: Population-based clinical cancer registry; N/A: Not applicable; nCT: Neoadjuvant chemotherapy; nCRT: Neoadjuvant chemoradiotherapy; AC: Adenocarcinoma.

**Pathological complete response**

Data from eight studies, covering a total of 1547 patients, were analyzed[35,36,39-44]. The OR (pooled effect size) was 0.27 (95%CI: 0.16-0.46). A significant difference was observed, favoring nCRT over nCT ($P < 0.001$). Between-study heterogeneity, expressed as the $I^2$ value, was 0.29 (95%CI: 0-0.68; Figure 2).

**Thirty-day mortality**

Data from four studies, including 899 patients, were analyzed[38,40,41,43]. The OR was 0.4 (95%CI: 0.22-0.71). A significant difference was observed, favoring nCRT over nCT ($P = 0.015$), with no between-study heterogeneity ($I^2$ value:
### Table 2 Characteristic of the neoadjuvant regimen, n (%)  

<table>
<thead>
<tr>
<th>Ref.</th>
<th>nCT</th>
<th>nCRT</th>
<th>Irradiation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chemotherapy</td>
<td>Chemotherapy</td>
<td>Irradiation</td>
</tr>
<tr>
<td></td>
<td>15 × weekly CFFa</td>
<td>15 × weekly CFFa followed by 3 wk course of CRT + 1 cycle CE</td>
<td>30 Gy in 15 fractions of 2 Gy in 3 wk</td>
</tr>
<tr>
<td>Stahl et al[44], 2017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burmeister et al[43], 2011</td>
<td>C (80 mg/m^2) + iv 5-FU (1000 mg/m^2/d) on days 1 and 21</td>
<td>CF + RT, 5-FU reduced to 800 mg/m^2/d (on day 21)</td>
<td>35 Gy in 15 fractions in 3 wk (on day 21)</td>
</tr>
<tr>
<td>Visser et al[42], 2018</td>
<td>OEO2</td>
<td>OEO2 + RT</td>
<td>35 Gy in 15 fractions or 45 Gy in 25 fractions</td>
</tr>
<tr>
<td></td>
<td>MAGIC</td>
<td>DCF (2 cycles pre-operatively) + RT</td>
<td>45 Gy in 25 fractions</td>
</tr>
<tr>
<td></td>
<td>DCF (2 cycles pre-operatively)</td>
<td>CROSS (since 2015)</td>
<td>41.4 Gy in 23 fractions of 1.8 Gy in 5 wk</td>
</tr>
<tr>
<td></td>
<td>Cisplatin + 5-FU: 92 (70)</td>
<td>Cisplatin + 5-FU: 94 (72)</td>
<td>35 Gy: 69 (53)</td>
</tr>
<tr>
<td></td>
<td>Epirubicin, cisplatin, 5-FU: 30 (23)</td>
<td>Epirubicin, cisplatin, 5-FU: 2 (2)</td>
<td>41 Gy: 14 (11)</td>
</tr>
<tr>
<td></td>
<td>Carboptatin + paclitaxel: 0 (0)</td>
<td>Carboptatin + paclitaxel: 20 (15)</td>
<td>45 Gy: 40 (31)</td>
</tr>
<tr>
<td></td>
<td>Other: 9 (7)</td>
<td>Other: 15 (11)</td>
<td>Other: 8 (6)</td>
</tr>
<tr>
<td>Markar et al[41], 2017</td>
<td>mainly MAGIC, OEO2 or OEOS regimens[8,10,45]</td>
<td>CROSS regimen[7,46]</td>
<td>41.4 Gy in 23 fractions of 1.8 Gy in 5 wk</td>
</tr>
<tr>
<td>Goense et al[46], 2017</td>
<td>ECX</td>
<td>CROSS regimen[7,46]</td>
<td>41.4 Gy in 23 fractions of 1.8 Gy in 5 wk</td>
</tr>
<tr>
<td>Favi et al[39], 2017</td>
<td>FLOT[47]</td>
<td>CROSS regimen[7,46]</td>
<td>41.4 Gy in 23 fractions of 1.8 Gy in 5 wk</td>
</tr>
<tr>
<td>Anderegg et al[35], 2017</td>
<td>ECX</td>
<td>CROSS regimen[7,46]</td>
<td>41.4 Gy in 23 fractions of 1.8 Gy in 5 wk</td>
</tr>
<tr>
<td>Spicer et al[38], 2016</td>
<td>Cornell: Platinum or taxane-based doublet, or both</td>
<td>concurrent ChT + RT</td>
<td>50.4 Gy</td>
</tr>
<tr>
<td></td>
<td>McGill: DCF (3 cycles)[48]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luc et al[56], 2015</td>
<td>DCF (3 cycles pre- and postoperatively)</td>
<td>continuous iv 5-FU 750 mg/m^2/d on days 1–5 by, C 20 mg/m^2 on day 1</td>
<td>45 Gy for 5 d per week at 1.8 Gy/d (started on day 28 along with the second CT cycle)</td>
</tr>
<tr>
<td>Münch et al[57], 2018</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

OEO2: Two cycles of cisplatin and 5-fluorouracil (5-FU). OEOS: Five cycles of cisplatin and 5-FU. CFFa: 15 × weekly 5-FU (2000 mg/m^2; 24 h infusion)/Fa (500 mg/m^2; 2 h infusion) and biweekly cisplatin (50 mg/m^2, 1 h infusion), in 14 wk. MAGIC: Protocol epirubicin, cisplatin, and 5-FU for three cycles before and three cycles after esophagectomy (EGJ Siewert II EAC and good vital status). DCF: Docetaxel 75 mg/m^2 (on day 1), cisplatin 75 mg/m^2 (on day 1), and 5-FU 750 mg/m^2/d by continuous infusion on days 2–5, (day 1 = day 22 = day 43). CROSS: With concurrent weekly administration of carboplatin (targeted at an area under the curve of 2 mg/mL per min) and paclitaxel (50 mg/m^2 of body-surface area). Forty-one four Gy in 23 fractions of 1.8 Gy in 5 wk. FLOT: 5-FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m^2 every 2 wk. ECX: Pre- and postoperative 3-wk cycles epirubicin (50 mg/m^2) and cisplatin (60 mg/m^2), followed by 1000 mg/m^2 of capcitabine twice daily for 14 d or 625 mg/m^2 of capcitabine twice daily for 21 d. Adaptations to the regimen such as dose reduction or change of regimen to oxaliplatin or 5-FU were applied when necessary. C: Cisplatin; F: Flurouracil; P: Paclitaxel; Fa: Folinic acid; E: Etoposide; N/A: Not applicable; nCT: Neoadjuvant chemotherapy; nCRT: Neoadjuvant chemoradiotherapy; AC: Adenocarcinoma; CRT: Chemoradiotherapy; CT: Chemotherapy; RT: Radiotherapy; 5-FU: 5-fluorouracil.

0; 95%CI: 0.40-0.85; Figure 3).

**Ninety-day mortality**

Data from four studies, encompassing 108 patients, were analyzed[38,40-42]. The OR was 0.71 (95%CI: 0.28-1.84). No significant difference was observed between nCRT and nCT (P = 0.34), with no between-study heterogeneity (I^2 value: 0; 95%CI: 0.40-0.85; [Supplementary Figure 1]).

**Overall survival**

The KM curves and logHR analysis conducted for eight studies encompassing 1540 patients did not reveal significant differences between the two groups in terms of overall survival (P = 0.82)[36-42,44]. The OR was 0.98 (95%CI: 0.77-1.23) and between-study heterogeneity was 0.35 (95%CI: 0.71-0.71; Figures 4 and 5).

Considering the 12-month overall survival (OS), nine studies including 1588 patients were selected for analysis[36-44]. The OR was 1.08 (95%CI: 0.8-1.46). No significant difference was observed between the two groups (P = 0.551). The between-study heterogeneity was 0.05 (95%CI, 0-0.67; [Supplementary Figure 2]). The log HR analysis revealed no
significant differences between the groups (Supplementary Figure 3).

For the 24-month OS, the OR was 1.03 (95%CI: 0.73-1.45)[36-44]. No significant difference was observed between the two groups (P = 0.858). The between-study heterogeneity was 0.42 (95%CI: 0.07;3; Supplementary Figure 4). The log HR analysis revealed no significant differences between the groups (Supplementary Figure 5).

Considering the 36-month OS, the OR was 0.93 (95%CI: 0.54-1.61)[36-44]. No significant difference was observed between the two groups (P = 0.754). The between-study heterogeneity was 0.73 (95%CI: 0.47-0.86; Supplementary Figure 6). The logHR analysis revealed no significant differences between the groups (Supplementary Figure 7).

Considering the 48-month OS, seven studies including 1066 patients were selected for analysis[36-38,40,42-44]. The OR was 0.67 (95%CI: 0.27-0.85). No significant difference was observed between the two groups (P = 0.616). The between-study heterogeneity was 0.67 (95%CI: 0.27-0.85; Supplementary Figure 8). The log HR analysis revealed no significant differences between the groups (Supplementary Figure 9).

Considering the 60-month OS, the OR was 1.15 (95%CI: 0.56-2.35)[36-38,40,42-44]. No significant difference was observed between the two groups (P = 0.658). The between-study heterogeneity was 0.67 (95%CI: 0.27-0.85; Supplementary Figure 10).

Disease-free survival

The KM curves and logHR analysis conducted for two studies including 578 patients did not reveal significant differences in overall survival between the two groups (P = 0.85)[36,38,42]. The OR was 1.04 (95%CI: 0.5-2.16). The between-study heterogeneity was 0.49 (95%CI: 0.08; Supplementary Figures 11 and 12).

Considering the 12-month Disease-free survival (DFS), the OR was 0.93 (95%CI: 0.44-1.97)[36,38,42]. No significant difference was observed between the two groups (P = 0.702). The between-study heterogeneity was 0.07 (95%CI: 0.09; Supplementary Figure 13). The logHR analysis revealed no significant differences between the groups (Supplementary Figure 14).

Considering the 24-month DFS, the OR was 0.95 (95%CI: 0.49-1.86)[36,38,42]. No significant difference was observed between the two groups (P = 0.789). The between-study heterogeneity was 0 (95%CI: 0-0.9; Supplementary Figure 15). The logHR analysis revealed no significant differences between the groups (Supplementary Figure 16).
Considering the 36-month DFS, the OR was 0.96 (95% CI: 0.4-2.28) [36,38,42]. No significant difference was observed between the two groups ($P = 0.846$). The between-study heterogeneity was 0.05 (95% CI: 0-0.9) was calculated (Supplementary Figure 17). The log HR analysis revealed no significant differences between the groups (Supplementary Figure 18).

Considering the 48-month DFS, the OR was 1.04 (95% CI: 0.31-3.51) [36,38,42]. No significant difference was observed between the two groups ($P = 0.904$). The between-study heterogeneity was 0.32 (95% CI: 0-0.9; Supplementary Figure 19). The log HR analysis revealed no significant differences between the groups (Supplementary Figure 20).

Considering the 60-month DFS, the OR was 1.04 (95% CI: 0.3-3.64) [36,38,42]. No significant difference was observed between the two groups ($P = 0.913$). The between-study heterogeneity was 0.32 (95% CI: 0-0.93) between the groups (Supplementary Figure 21).

**Progression-free survival**

For the 12-month progression-free survival (PFS), three studies including 340 patients were selected for analysis [40,43,44]. The OR was 0.73 (95% CI: 0.47-1.16). No statistically significant was observed difference between the two groups ($P = 0.101$). The between-study heterogeneity was 0 (95% CI: 0-0.9; Supplementary Figure 22).
Considering the 24-month PFS, the OR was 0.78 (95% CI: 0.1-6.18) [40,43,44]. No significant difference was observed between the two groups (\(P = 0.652\)). The between-study heterogeneity was 0.72 (95% CI: 0.04-0.92; Supplementary Figure 23).

Considering the 36-month PFS, the OR was 1.04 (95% CI: 0.1-11.05) [40,43,44]. No significant difference was observed between the two groups (\(P = 0.964\)). The between-study heterogeneity was 0.81 (95% CI: 0.39-0.94; Supplementary Figure 24).

**Locoregional recurrence**

Data from six studies including 1037 patients were analyzed, revealing locoregional recurrence in 12% of the patients [36, 37,41-44]. The OR was 0.98 (95% CI: 0.35-2.77). No significant difference was observed between the two groups (\(P = 0.966\)). The between-study heterogeneity was 0.76 (95% CI: 0.47-0.89; Supplementary Figure 25).

**Distant metastasis recurrence**

Data from five studies including 910 patients were analyzed, revealing distant metastasis recurrence in 39% of the patients [37,41-44]. The OR was 1.12 (95% CI: 0.76-1.64). No significant difference was observed between the two groups (\(P = 0.462\)). The between-study heterogeneity was 0 (95% CI: 0-0.79; Supplementary Figure 26).

**Thromboembolism events**

Data from four studies including 818 patients were analyzed for the occurrence of thromboembolism events [35,40,42,43]. The OR was 1.93 (95% CI: 0.1-38.65). No significant difference was observed between the two groups (\(P = 0.535\)). The between-study heterogeneity was 0.72 (95% CI: 0.22-0.90; Supplementary Figure 27).

**Cardiac complications**

Data from seven studies including 1580 patients were analyzed for the occurrence of cardiac complications [35,36,38,40-43]. The OR was 0.8 (95% CI: 0.42-1.52). No significant difference between the two groups (\(P = 0.425\)). The between-study heterogeneity was 0.46 (95% CI: 0-0.77; Supplementary Figure 28).

**Respiratory complications**

Data from seven studies including 1580 patients were analyzed for the occurrence of respiratory complications [35,36,38,40-43]. The OR was 1.04 (95% CI: 0.66-1.64). No significant difference was observed between the two groups (\(P = 0.835\)). The between-study heterogeneity was 0.59 (95% CI: 0.04-0.82; Supplementary Figure 29).

**Renal failure**

Data from three studies including 650 patients were analyzed for the occurrence of renal failure [35,42,43]. The OR was 2.43 (95% CI: 1.12-5.28). A statistically significant difference was observed, favoring nCT over nCRT (\(P = 0.039\)). The between-study heterogeneity was 0 (95% CI: 0-0.9; Supplementary Figure 30).

**Neutropenia**

Data from three studies including 560 patients were analyzed for the occurrence of neutropenia [35,40,43]. The OR was 0.97 (95% CI: 0.09-10.29). No significant difference was observed between the two groups (\(P = 0.964\)). The between-study heterogeneity was 0.47 (95% CI: 0-0.84; Supplementary Figure 31).

**Anastomotic leakage**

Data from seven studies including 1580 patients were analyzed for the occurrence of anastomotic leakage [35,36,38,40-43]. The OR was 0.83 (95% CI: 0.41-1.68). No significant difference was observed between the two groups (\(P = 0.539\)). The between-study heterogeneity was 0.75 (95% CI: 0.48-0.88; Supplementary Figure 32).

**Chyle leakage**

Data from six studies including 1366 patients were analyzed for the occurrence of chyle leakage [35,36,40-43]. The OR was 0.99 (95% CI: 0.61-1.61). No significant difference was observed between the two groups (\(P = 0.961\)). The between-study heterogeneity was 0 (95% CI: 0-0.75; Supplementary Figure 33).

**Wound infection**

Data from five studies including 1022 patients were analyzed for the occurrence of wound infection [35,38,40,42,43]. The OR was 1.04 (95% CI: 0.36-3.02). No significant difference was observed between the two groups (\(P = 0.930\)). The between-study heterogeneity was 0.37 (95% CI: 0-0.76; Supplementary Figure 34).

**Bleeding**

Data from four studies including 849 patients were analyzed for the occurrence of bleeding [35,36,40,42]. The OR was 1.4 (95% CI: 0.425-7.79). No statistically significant difference was observed between the two groups (\(P = 0.581\)). The between-study heterogeneity was 0 (95% CI: 0-0.85; Supplementary Figure 35).
Vocal cord paresis
Data from three studies including 733 patients were analyzed for the occurrence of vocal cord paresis[35,40,42]. The OR was 1.21 (95%CI: 0.04-41.98). No significant difference was observed between the two groups (P = 0.537). The between-study heterogeneity was 0.5 (95%CI: 0-0.85; Supplementary Figure 36).

Leukopenia
Two studies including 485 patients were selected for descriptive analyses[35,40]. Leukopenia occurred in 8% and 12% of the patients in the nCT and nCRT groups, respectively.

Anemia
Two studies including 485 patients were selected for descriptive analyses[35,40]. Anemia occurred in 1% and 0.4% of the patients in the nCT and nCRT groups, respectively.

Nausea or vomiting
Three studies including 560 patients were selected for descriptive analyses[35,40,43]. Nausea or vomiting occurred in 9% and 3% of the patients in the nCT and nCRT groups, respectively.

Diarrhea
Two studies including 485 patients were selected for descriptive analyses[35,40]. Diarrhea occurred in 7% in the nCT group, whereas no cases were noted in the nCRT group.

Hospital stay
Two studies including 430 patients were selected for descriptive analyses[40,42]. The estimated mean hospital stay was 20 (range: 7-97) d in the nCT group and 18 (range: 7-75) d in the nCRT group.

Risk of bias
As we expected, the two RCTs demonstrated a low risk of bias. However, for other included trials, ROB2 indicated some concerns, mainly due to the randomization process (D1). In one trial, concerns were noted regarding the measurement process due to the utilization of a plot digitizer[17]. No instance of high risk of bias was identified across the included studies. Additional information is presented in Table 3.

GRADE approach
Employing the GRADE approach, our findings were determined to have low certainty for most outcomes; moderate certainty for 30-d mortality; very low certainty for 12-month OS, 36-month PFS, and the occurrence of thromboembolism events. The use of ROB2 indicated a moderate risk for all outcomes. High heterogeneity was reported for 36-month PFS and the occurrence of thromboembolic events. Imprecision was observed for pCR and 12-month OS. Additionally, a high variation in oncological treatments decreased the evidence quality, whereas a large effect size increased the quality of pCR and 30-d mortality[49] (Supplementary Table 4).

DISCUSSION
The benefits of neoadjuvant therapy have been previously reported[7-9]. Previous meta-analyses have examined the amplification of nCT and chemoradiotherapy in patients with AC or SCC. In the nCRT group, advantages were observed in terms of 3-year survival with R0 resection; however, the pCR rate had no effect on long-term survival. Perioperative mortality and cardiovascular complications are more common in patients with AC in the nCRT group[30]. A previous network meta-analysis showed that triplet-based chemotherapy increases overall survival and DFS in cases of AC of the stomach or GEJ[51].

pCR is defined as the lack of tumor in the resected specimen or lymph nodes (pT0 pN0 cM0)[15,36]. The 5-year survival rate is presumably 88% in patients with pCR compared to 39% in those without pCR[15,52]. According to a recent investigation comparing the long-term survival of the total population and patients with TRG grade 1-2 who underwent nCT or chemoradiotherapy before surgery revealed that tumor regression after neoadjuvant treatment is significantly associated with long-term survival, regardless of the treatment regimen[53]. Another retrospective cohort study revealed improved OS and DFS in patients who achieved pCR following nCT compared to those who achieved a lower rate of pCR following nCRT. The authors found a significant association between TRG and survival in both the groups. Additionally, patients who achieved pCR in the nCRT group did not have as good a survival rate as those in the nCT group, although their proportion was higher in the nCRT group. This finding suggests that esophageal AC should be considered a systemic disease and treated accordingly[53,54]. However, other trials have reported that a larger number of patients who achieved pCR do not have improved overall survival[55]. In this meta-analysis, we found a significantly higher pCR in the nCRT group; however, no differences were found in OS, DFS, or PFS, consistent with the findings of previous meta-analyses[50,55]. Based on this finding, we inferred that there is no association between pCR and OS; therefore, the use of pCR as a prognostic factor should be considered in cases of AC. These findings aligned with those of Gebauer et al’s study[36] reporting that high pCR after CROSS regimen is not clearly associated with longer overall survival[56]. Another study concluded that only clinically complete response without nodal metastasis is associated with
long-term survival; therefore, the “watch-and-wait” strategies should be considered carefully and applied only to patients who have achieved pCR [57]. The utility of pCR as a prognostic indicator of neoadjuvant therapy remains questionable, indicating the need for large number of randomized studies in the future.

Our analysis revealed that none of the investigated groups were superior considering local recurrence, which aligns with the findings of a previous meta-analysis [50]. This indicates that the higher local control provided by radiotherapy does not reduce the incidence of local recurrence. Additionally, we did not detect a significant difference in terms of metastases, which occurred in 39% of the cases compared to 12% of local recurrence cases, suggesting that AC should be treated as a systematic disease, and therefore, the “watch-and-wait” strategies should be considered critically.

Our findings revealed a significantly higher 30-d mortality risk in the chemoradiotherapy group. This can be attributed to complications arising in the postoperative period. However, differences in the outcomes of surgical complications were not noted, consistent with the findings of a previous meta-analysis, in which no difference was reported in anastomotic leakage [50]. Additionally, a previous meta-analysis reported a higher risk of mortality in the postoperative period among patients with AC. Therefore, further investigation into the effects of nCRT on postoperative complications is warranted [50]. We only performed descriptive analysis, which revealed a comparable duration of postoperative hospitalization in both the groups [40,42].

We observed no difference in any of the clinical complications in both the groups; however, a previous meta-analysis reported a higher risk of cardiovascular complications in the nRCT group than in the nCT group, which could be a toxic side effect of this modality.

nCT and radiotherapy are also associated with adverse events, including thromboembolic events, neutropenia, leukopenia, anemia, nausea or vomiting, and diarrhea [35]. Renal failure occurred more often in the nCT group than in the nCRT group, indicating a toxic side effect of nCT. However, no difference was reported in terms of cardiac failure, in contrast to a former meta-analysis [50]. According to previous investigations, neutropenia is not associated with either neoadjuvant treatment modality. In the descriptive analysis, leukopenia occurred 4% more frequently in the nCRT group than in the nCT group, making them more vulnerable to developing infections. Additionally, a low number of anemia cases was observed in both the groups. The quality of life can be assessed using the EORTC QLQ-C30 questionnaire [58], which includes encompasses side effects including nausea, vomiting, and diarrhea. Notably, these side effects occurred approximately 7% more frequently in the nCT group than in the nCRT group.

Our meta-analysis provides the most comprehensive and recent summary of the data, particularly focusing on patients with esophageal AC. In addition, various outcomes were analyzed in a sufficient number of patients. The data from this study accurately reflect the esophageal AC population. No significant differences in demographic characteristics were reported between patients of the two groups.

Nevertheless, our study has some limitations. Deviating from the protocol, we included propensity score-matched studies and cohort trials, which are less reliable than RCTs and have potentially significant biases. Additionally, all trials were conducted in Western countries, reflecting a characteristic of AC, thus limiting the generalizability of the results to the Asian population or other countries. The use of various neoadjuvant regimens and some the lack of separation between preoperative and perioperative therapies in some included studies also pose some limitations. Furthermore, the evidence for most outcomes was deemed low; therefore, the true effect may differ substantially from the estimate.

In summary, one might question the lack of impact of radiotherapy on overall survival, despite improvements in measures of pathological regression, known to correlate with survival. This discrepancy can be attributed to modification of these crucial measures by local therapy. In the context of modern surgical techniques, the systemic component of the disease is the primary determinant of survival in esophageal and gastroesophageal junction ACs. Hence, the incorporation of systemic chemotherapy, new immunotherapies, and targeted treatments capable of addressing distant
diseases holds greater potential to enhance patient survival in the future.

**CONCLUSION**

In patients with esophageal AC, neoadjuvant chemoradiation increases pCR and 30-d mortality; however, it has no effect on long-term survival. nCT may be associated with side effects that can decrease the quality of life. Further randomized trials are required to address the limitations in the quality of the available studies.

**ARTICLE HIGHLIGHTS**

**Research background**

The incidence of adenocarcinoma (AC) in the esophagus is increasing, especially in the Western countries, in contrast to the incidence of squamous cell carcinomas (SCC). Neoadjuvant therapy before surgery can improve patient survival in advanced stages. The superiority of neoadjuvant modalities, especially for ACs, remains unclear. Previous meta-analyses have numerous limitations, including the pooled populations of AC and SCC, which makes the application of their results specifically to either subtype difficult.

**Research motivation**

The superiority of neoadjuvant therapy has been proven previously; however, determining which modality has a greater benefit, especially for esophageal AC, remains uncertain. In this study, we performed a comprehensive, up-to-date investigation to compare the efficacy of neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) in the surgical treatment of AC of the esophagus and esophageal junction.

**Research objectives**

To address the questions of this meta-analysis, we used the PICO protocol to evaluate data from patients with esophageal or cardiac AC, who underwent neoadjuvant therapy before surgery. Intervention was preoperative nCT, which was compared with nCRT. We investigated the following outcomes: Survival, remission rate, mortality, short- and long-term clinical and surgical complications, and quality of life.

**Research methods**

Following the PICO protocol, two authors independently performed a comprehensive search of multiple databases using the predefined criteria. Statistical analyses were performed by biostatisticians to calculate odds ratio and hazard ratio with the 95%CI. Results were visualized using forest plots and Kaplan-Meier curves. The Risk of Bias Tool 2 and GRADE approach were used to assess the quality of the results.

**Research results**

Ten articles were included after selection. After statistical analysis, we observed that 30-d mortality ($P = 0.015$) and pathological complete response ($P < 0.001$) were higher in the nCRT group than in the nCT group; however, no significant difference was observed for long-term survival. The risk of renal failure ($P = 0.039$) was higher in the nCT group, and the incidence of nausea or vomiting was 9% in the nCT group compared to 3% in the nCRT group. No significant difference was reported in other clinical or surgical complications.

**Research conclusions**

Although the superiority of neoadjuvant therapy has been previously demonstrated, nCRT may increase pathological complete response and 30-d mortality, without improving long-term survival. Furthermore, nCT may lead to some adverse effects, which can decrease the quality of life.

**Research perspectives**

The present study predominantly analyzed retrospective data, potentially introducing research bias; therefore, future randomized studies with more detailed data collection are warranted.

**FOOTNOTES**

**Author contributions:** Csontos A contributed to the design and implementation of the study and the writing of the manuscript; Fazekas A and Farkas N contributed to the statistical analyses and the writing of the manuscript; Szakó L contributed to the design of the study and the revision of the manuscript; Papp C and Ferenczi S contributed to the performance of the research; Belleyei S and Hegyi P contributed to the quality and professional revision; Papp A contributed to the quality and professional revision and the writing of the manuscript.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have reviewed the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Hungary

ORCID number: Armand Csontos 0000-0002-0204-0642; Lajos Szakó 0000-0001-9783-4076; Nelli Farkas 0000-0002-5349-6527; Péter Hegyi 0000-0001-0399-7259; András Papp 0000-0002-2845-531X.

S-Editor: Li L
L-Editor: A
P-Editor: Cai YX

REFERENCES


radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.


Csontos A et al. Impact of neoadjuvant therapy of esophageal adenocarcinoma


